TCOM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TCOM is not a good buy right now for an impatient investor. The stock is technically oversold and could bounce, but the dominant near-term driver is event risk (China antitrust investigation + expanding securities-law-firm investigations/class-action headlines). That news overhang can keep pressure on the share price regardless of fundamentals. With no Intellectia buy signals today and sentiment skewed toward hedging, the risk/reward does not favor buying immediately.
Intellectia Proprietary Trading Signals
Trend/condition: Bearish-to-stabilizing after a sharp selloff. MACD histogram is negative (-0.506) but contracting, which often signals downside momentum is fading (early stabilization, not a confirmed reversal).
RSI: RSI(6)=29.26 is near oversold territory, supporting the idea of a short-term relief bounce potential.
Moving averages: Converging MAs suggest price is compressing after the drop; this is consistent with basing, but not yet an uptrend.
Key levels: Pivot=62.18 is immediate reclaim level. Support: S1=60.61 then S2=59.64. Resistance: R1=63.74 then R2=64.71. With post-market at 61.37 (below pivot), price remains technically "under pressure" unless it can reclaim and hold above ~62.2.
Quant pattern read: Similar-pattern stats imply slightly negative next-day/next-week drift (-0.6% next day; -0.15% next week) and a modest positive 1-month bias (+2.37%), aligning with a choppy base before any recovery.
Fundamentals were strong in the latest reported quarter (2025/Q3): revenue +15.53% YoY with very strong net income/EPS growth, implying operating leverage.
Hedge funds are reported as net buyers, with buying amount up ~118.94% over the last quarter.
Analyst community (as of Nov
remained constructive with multiple Buy/Overweight ratings and raised price targets (low-to-mid $80s up to $90), implying meaningful upside if regulatory risk fades.
Technical setup is near-oversold (RSI(
~29), which can support a reflex rally if headlines cool.
Primary overhang: disclosed antitrust investigation by Chinese regulators; this is a high-impact, hard-to-time catalyst that can drive further downside and headline volatility.
Multiple Rosen Law Firm investigation/class-action-related headlines (Jan 23–29,
can suppress sentiment and keep risk premium elevated.
Price is still below the key pivot (~62.
with MACD negative, so the chart has not confirmed a reversal.
Options open-interest put/call >1 suggests ongoing protective positioning.
Latest quarter: 2025/Q3. Revenue rose to 18.338B (+15.53% YoY), showing continued growth. Net income increased sharply (+194.01% YoY) and EPS jumped (+188.22% YoY), indicating strong profitability/operating leverage versus last year. Gross margin slipped slightly to 81.68% (-0.83% YoY), a modest negative but not enough to offset the strong earnings momentum overall.
Recent trend (latest updates in Nov 2025): Analysts were uniformly positive post-Q3 results, with multiple firms reiterating Buy/Overweight and raising price targets (BofA to $85, Barclays to $90, Citi to $86, Benchmark to $82). Wall Street pros: strong bookings/volume growth, disciplined spending, and resilience vs broader consumption slowdown. Cons: these targets pre-date the January 2026 antitrust headline cycle, so near-term "street" optimism may not fully reflect the updated regulatory risk premium.
Influential/political trading check: No recent congress trading data available; insiders were reported neutral; no politician/influential-figure trading provided in the dataset.
